Ascendia

  MARKET NEWS

Strata Oncology Announces Addition of Gilead as Strata PATH Trial Collaborator
BriaCell Announces Positive End of Phase 2 Meeting With the FDA for Bria-IMT Combination in Advanced Metastatic Breast Cancer
Avidity Biosciences Granted FDA Fast Track Designation for the Treatment of Facioscapulohumeral Muscular Dystrophy
Ingenza Collaborates With Amplifica to Advance Novel Alopecia Treatments
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis & Discloses Clinical Development Plan
TTP introduces Cellular Origins, Focused on Delivering Ccalable Manufacture of Cell & Gene Therapies

  FEATURED EDITORIAL

  COMPANY PROFILE

BIOVECTRA is a full-service CDMO specializing in the clinical-to-commercial-scale production of high-quality regulated APIs and intermediates, including biologics, synthetic small molecules, pDNA and mRNA, highly potent APIs, and bioreagents. Our teams leverage decades of expertise and a proven track record of excellence to optimize, adapt, and perfect innovative technologies and drug substance development approaches to deliver world-class solutions for pharmaceutical manufacturing. Click here for more.

  EXCLUSIVE ONLINE CONTENT

SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination With Cetuximab

SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination With Cetuximab

SOTIO Biotech recently announced the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa (previously known as SOT101), an IL-15 superagonist, and….

Evaxion Receives FDA Fast-Track Designation for Personalized Cancer Immunotherapy

Evaxion Receives FDA Fast-Track Designation for Personalized Cancer Immunotherapy

Evaxion Biotech A/S recently announced the US FDA has granted fast track designation for the company’s personalized cancer therapy, EVX-01, in combination….

Teon Therapeutics Announces Clinical Trial Collaboration With Merck to Evaluate Novel Oral Immune Response Modifier in Combination with KEYTRUDA

Teon Therapeutics Announces Clinical Trial Collaboration With Merck to Evaluate Novel Oral Immune Response Modifier in Combination with KEYTRUDA

Teon Therapeutics (Teon) recently announced it has entered into the clinical trial collaboration agreement with Merck for the combination arm of Teon’s ongoing, two-armed, open-label, dose….

Needle-Free Patch Technology for mRNA Vaccines Aims to End Need for Frozen Storage & Improve Access

Needle-Free Patch Technology for mRNA Vaccines Aims to End Need for Frozen Storage & Improve Access

CEPI, the Coalition for Epidemic Preparedness Innovations, and Vaxxas have recently signed a partnership agreement to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology in a project….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening

WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening

Abstract: A team of bioavailability experts at Catalent used the in-house bioavailability enhancement platform, OptiForm® Solution Suite, to optimize and develop Phase 1 clinical formulation within a short timeline. Catalent’s global supply chain expertise was utilized for packaging and distributing …

WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)

WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)

Abstract: Catalent’s proprietary Zydis® ODT platform is backed by a large number of clinical studies. This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets. Factors addressed include bioavailability, safety, side effects, speed/pharmacokinetics, variability, …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 1 – Analytical Testing
February 8 – Injection Devices